| Filed On | Filing |
|---|---|
| 06 Nov 2026 | SCHEDULE 13D/A |
| 05 Nov 2026 |
Form 4: Paganelli John A, Director
Sold 13,601 shares ($24.6K) |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
MIAMI, November 4, 2026 – OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business highlights and financial results for the third quarter ended September 30, 2026. |
| 15 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
CERTAIN INFORMATION CONTAINED IN THIS AGREEMENT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PR... |
| 02 Oct 2026 |
8-K: Other Events
On October 1, 2026, OPKO Health, Inc. (the “Company”) determined that its 3.75% Convertible Senior Notes due 2029 (the “Notes”), of which approximately $121 million is outstanding, are convertible by holders of such Notes through Decembe... |
| 28 Aug 2026 | 10-Q/A |
| 28 Aug 2026 | 10-Q/A |
| 14 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On August 13, 2026, OPKO Health, Inc. (the “Company”) entered into an amendment (the “Amendment”) to the initial Note Purchase Agreement dated July 17, 2024 (the “Original Agreement”; and as amended by the Amendment, the “Amended Agreeme... |
| 07 Aug 2026 | SCHEDULE 13D |
| 28 Jul 2026 |
Form 4: Logal Adam, Sr. Vice President, CFO
Gave up 53,266 shares to cover exercise price or tax ($65K) |
| 28 Jul 2026 |
Form 4: Rubin Steven D, Director
Gave up 53,266 shares to cover exercise price or tax ($65K) |
| 27 Jul 2026 | 10-Q |
| 27 Jul 2026 |
8-K: Results of Operations and Financial Condition
MIAMI, July 27, 2026 – OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today reports business highlight... |
| 01 Jul 2026 | SCHEDULE 13D/A |
| 22 Jun 2026 |
Form 4: Lachman Prem A, Director
Granted 30,000 Stock Option (Right to Buy) |
| 22 Jun 2026 |
Form 4: Medel Roger Md, Director
Granted 30,000 Stock Option (Right to Buy) |
| 22 Jun 2026 |
Form 4: Paganelli John A, Director
Granted 30,000 Stock Option (Right to Buy) |
| 22 Jun 2026 |
Form 4: Pfenniger Richard C Jr, Director
Granted 60,000 Stock Option (Right to Buy) |
| 22 Jun 2026 |
Form 4: Uppaluri Subbarao V, Director
Granted 80,000 Stock Option (Right to Buy) |
Loading...